Key Highlights
- 10.41% is the one-week gain in Privia Health (NASDAQ:PRVA), which traded at USD 22.43 on October 16, 2026 per published market data, with the 14-day RSI at 70.6. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.
- 21.4% is the second quarter revenue growth to USD 632.6 million, per the company release dated August 6, 2026. Adjusted EBITDA rose 29.1% to USD 37.4 million, and GAAP net income attributable to Privia was USD 9.0 million.
- 1,647,000 attributed lives were reported at the end of the second quarter, up 19.2%. Privia Health (NASDAQ:PRVA) raised its full-year lives guidance to 1,625,000 to 1,650,000 from 1,550,000 to 1,600,000 in the August 6, 2026 release.
- November 5, 2026 is the date for third quarter results, before the market opens, with the release due by 7:00 a.m. ET and a call at 8:00 a.m. ET, per the company announcement dated October 8, 2026.
Value-Based Care at a Premium
The stake: can a thin-margin growth story earn a rising multiple? Privia Health (NASDAQ:PRVA) enables physician groups and manages value-based contracts, earning revenue when patient populations cost less than benchmarks. Second quarter GAAP net income of USD 9.0 million on USD 632.6 million of revenue is a 1.4% margin, own arithmetic, while adjusted EBITDA of USD 37.4 million is a 5.9% margin. Growth is the selling point: attributed lives of 1,647,000 are 19.2% higher. Privia announced the Evolent ACO purchase on September 23, 2025 for USD 100 million in cash plus up to USD 13 million contingent on 2025 Medicare Shared Savings Program results.
Guidance, Valuation and Positioning
The August 6, 2026 release set no new dollar ranges; it placed full-year results within the February 27, 2026 ranges. Practice collections and GAAP revenue are guided to the high end of USD 3,650 million to USD 3,750 million and USD 2,350 million to USD 2,450 million. Adjusted EBITDA is guided to the mid to high end of USD 145 million to USD 155 million. Against a USD 2.86 billion market capitalisation, the USD 150 million range midpoint is 19.1 times, own arithmetic, ignoring net cash, which is not disclosed in the releases reviewed. The 10.41% gain reprices a guided, not yet delivered, second half.
Risks and What Could Fade the Move
The 14-day RSI compares average gains with average losses; a reading above 70 flags a stretched short-term move and is not a forecast. Specific risks include contingent consideration tied to shared savings results, a 1.4% net margin and dependence on government programme benchmarks. Guidance at the mid to high end of ranges leaves limited room for disappointment. The test on November 5, 2026 is whether attributed lives and care margin stay within the raised outlook.
Where Things Stand
It depends: Privia Health (NASDAQ:PRVA) can extend a 10.41% weekly gain only if the November 5, 2026 results confirm that growth in attributed lives translates into earnings. Supportive evidence is 21.4% revenue growth, 29.1% adjusted EBITDA growth and a raised outlook. Constraints are a 1.4% GAAP net margin, a 19.1 times market capitalisation to EBITDA multiple and an RSI of 70.6. No company-specific catalyst explains the week, so momentum is the only identified driver. Third quarter results on November 5, 2026 are the next catalyst.






Please wait processing your request...